Home / Business and Economy / Nuwellis Surges Ahead with Outpatient Therapy and Pediatric Innovation
Nuwellis Surges Ahead with Outpatient Therapy and Pediatric Innovation
13 Nov
Summary
- 23% increase in consumables utilization and 4x rise in US console sales
- New 24-hour aqueduct circuit for hospital-based outpatient use
- First Aquadex therapy delivered in outpatient setting under new CMS code
- Advancing pediatric CRRT system Vivian with new US patent allowances
In the third quarter of 2025, Nuwellis Inc. (NASDAQ:NUWE) has seen significant progress in its business. The company reported a 23% increase in consumables utilization and a fourfold increase in US console sales sequentially from the second quarter. This growth was driven by strong performance in the heart failure and critical care categories, with year-over-year growth in circuit sales and stronger console demand.
Nuwellis has also introduced a new 24-hour aqueduct circuit for hospital-based outpatient use, providing flexibility and consistency in therapy. The company achieved a milestone with the first Aquadex therapy delivered in a hospital-based outpatient setting under a new CMS reimbursement code, demonstrating its commitment to expanding access to its innovative solutions.
Furthermore, Nuwellis is advancing its pediatric CRRT system, Vivian, with new US patent allowances, showcasing its dedication to innovation in pediatric fluid management. The company has also completed two successful capital raises, providing financial flexibility to support its US revenue growth strategy into 2026.
